Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$196.82 USD

196.82
2,946,862

-0.14 (-0.07%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sheraz Mian headshot

New Stock Research Reports for Boeing, AbbVie and UnitedHealth

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV) and UnitedHealth (UNH).

    Celgene's (CELG) Revlimid Looks Solid on Label Expansion

    Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.

      AbbVie and J&J Present Positive Imbruvica Leukemia Data

      AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).

        Infinity (INFI) Reports Narrower-than-Expected Loss in Q1

        Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.

          Arpita Dutt headshot

          Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

          Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.

            Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

            Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.

              AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y

              AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.

                AbbVie (ABBV) Beats Earnings and Revenue in Q1

                AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.

                  Tracey Ryniec headshot

                  5 Fantastic Earnings Charts

                  Tracey brings you the companies with the best earnings charts each week.

                    Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY

                    Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.

                      Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?

                      Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.

                        Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong

                        Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.

                          AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

                          AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)

                            What's in Store for AbbVie (ABBV) this Earnings Season?

                            AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.

                              What's in Store for Biogen (BIIB) this Earnings Season?

                              Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.

                                AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

                                AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.

                                  Repros' Proellex Continues to be Under Partial Clinical Hold

                                  Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver

                                    Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

                                    Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

                                      AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

                                      AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

                                        AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

                                        AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

                                          AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

                                          AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

                                            Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

                                            Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

                                              Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

                                              Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

                                                Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

                                                Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

                                                  Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

                                                  Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.